Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2014 | $120 M | No. 3 | $50 to $250 million | equity | SEC | |
| May 2012 | $18 M | No. 2 | $10 to $50 million | equity | SEC | |
| Dec 2009 | $25 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Proteus Biomedical Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2014).
SEC Form D · Jun 2014
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2014
That is all the official record says: Proteus Biomedical Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Proteus Biomedical Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 11 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew M. Thompson | Executive officer | Jun 2014 |
| Anthony J. Levitan | Executive officer | Jun 2014 |
| Ben M. Costello | Executive officer | Jun 2014 |
| David M. O'Reilly | Executive officer | Jun 2014 |
| Donald J. Cowling | Executive officer | Jun 2014 |
| George M. Savage | Executive officer | Jun 2014 |
| Mark J. Zdeblick | Executive officer | Jun 2014 |
| Markus J. Christen | Executive officer | Jun 2014 |
| Andrew Thompson | Executive officer | May 2012 |
| Benjamin L. Costello | Executive officer | May 2012 |
| David O'Reilly | Executive officer | May 2012 |
| Erika L. Karplus | Executive officer | May 2012 |
| George Savage | Executive officer | May 2012 |
| Joy Berberich | Executive officer | May 2012 |
| Lorenzo L. Di Carlo | Executive officer | May 2012 |
| Mark Zdeblick | Executive officer | May 2012 |
| Timothy L. Robertson | Executive officer | May 2012 |
| Todd Thompson | Executive officer | May 2012 |
| Alan J. Levy | Director | Jun 2014 |
| Andrew M. Thompson | Director | Jun 2014 |
| Frank J. Fischer | Director | Jun 2014 |
| Immanuel J. Thangaraj | Director | Jun 2014 |
| Jonathan J. Symonds | Director | Jun 2014 |
| Myrtle J. Potter | Director | Jun 2014 |
| Robert J. Epstein | Director | Jun 2014 |
| Ryan J. Schwarz | Director | Jun 2014 |
| Alan Levy | Director | May 2012 |
| Andrew Thompson | Director | May 2012 |
| Ben Pless | Director | May 2012 |
| Frank Fischer | Director | May 2012 |
| Immanuel Thangaraj | Director | May 2012 |
| Mark Zdeblick | Director | May 2012 |
| Ryan Schwarz | Director | May 2012 |
| Terry Gould | Director | May 2012 |